Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.16 | $-0.49 | $-0.42 |
| Estimado | $-0.40 | $-0.38 | $-0.41 | $-0.41 |
| Sorpresa | — | +57.9% | -19.5% | -2.4% |
| Métrica | OCS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -50.5% | -39.2% | -11.3% |
| ROA | -41.9% | -30.9% | -11.0% |
| Current Ratio | 5.96 | 2.73 | +3.23 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -41.9% | — |
| ✗Flujo de caja operativo positivo | −CHF 66M | −CHF 49M |
| ✓Rentabilidad sobre activos al alza | -41.9% | -71.3% |
| ✓Caja operativa/activos supera al ROA | -28.1% | ROA -41.9% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 5.96 | 2.37 |
| ✗Sin aumentar el nº de acciones | 52M | 40M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -41.0% |
Oculis Holding AG cotiza a 7.29 USD y tiene una capitalización bursátil de $449M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud